Treating Hypertension and Beyond: A New Perspective on the Renin-Angiotensin System (RAS)
Presented by The Johns Hopkins University School of Medicine
Supported through an educational grant from Novartis
The renin-angiotensin system (RAS) has been well-established in playing a key role in regulating blood volume, arterial pressure and cardiac and vascular function. The more recently developed classes of antihypertensive therapies, ACE inhibitors (ACEI) and angiotensin AT1-receptor blockers (ARBs), have proved to be highly successful treatments for hypertension, heart failure and related cardiovascular disorders. However, these compounds do not completely inhibit the RAS as a result of A II formation by indirect pathways and compensatory feedback mechanisms resulting in renin release. This incomplete inhibition theoretically can lead to greater end-organ damage.
A number of renin inhibitors (RIs) are currently in development. The RIs would provide upstream inhibition of RAS and block the production of both angiotensin I and II. Understanding the traditional RAS targets, and the potential role of RIs in practice represents a significant need for healthcare providers involved in the diagnosis and treatment of hypertensive patients.
DATE OF RELEASE AND EXPIRATION
This course was released on April 25, 2006 and will expire on April 25, 2007. Credit cannot be awarded after this date.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
Dr. Roger S. Blumenthal has received grants, research support and honorarium from Pfizer, Merck, Novartis, JKO, and Sanofi-Aventis.
Dr. Elizabeth Ofili He has served as a consultant for Bristol-Myers Squibb, Nitromed, Novartis, and Sanofi-Aventis.
Dr. Michael A. Weber He has served as a consultant for Boehring-Ingelheim, BMS, Novartis, Pfizer, Merck, Sanofi-Aventis, Sankyo
Dr. Matthew R. Weir has no relationships to disclose.
2006 the Johns Hopkins University School of Medicine. All rights reserved.
Please note, this link will take you to a website not maintained by Johns Hopkins University.
©2002-2003, Johns Hopkins University, School of Medicine, Office of
Continuing Medical Education
Privacy statement | Website design:
Kim Bieler Graphic Design